Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
Clinical trial NCT02501473 · TERMINATED
Trial details
- NCT number
- NCT02501473
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-03
- Primary completion
- 2019-08-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.